Healthcare Industry News: Bristol-Myers Squibb
News Release - May 22, 2008
Endo Pharmaceuticals Appoints Blaine T. Davis as Vice President, Investor Relations and Corporate CommunicationsCHADDS FORD, PA--(Healthcare Sales & Marketing Network)--May 22, 2008 -- Endo Pharmaceuticals Holdings Inc. (NasdaqGS:ENDP ) today announced that Blaine T. Davis has been appointed Vice President, Investor Relations and Corporate Communications. Mr. Davis will be responsible for the creation and implementation of strategic communications efforts that support Endo's business objectives to all key stakeholders, including investors, employees and the media. He will report directly to the President and Chief Executive Officer David P. Holveck.
"I am personally delighted that Blaine has decided to join Endo and look forward to working with him as we continue to build on Endo's success," said Mr. Holveck. "Blaine thoroughly understands our industry and throughout his career has demonstrated the ability to effectively apply his strong analytical and strategic skills to stakeholder communications."
Prior to joining Endo, Mr. Davis was Director of Alliance Management within the Corporate & Business Development unit at Bristol-Myers Squibb, where he was responsible for the overall management of the Bristol-Myers Squibb/AstraZeneca collaboration in diabetes. He joined Bristol-Myers Squibb in January 2005 as Director of Investor Relations where he managed the company's communication with the investment community as well as advised senior management on capital markets dynamics.
Prior to 2005, Mr. Davis was a Vice President/Sector Head in the Corporate Advisory Services group at Thomson Financial, where he led a team working primarily with publicly traded companies in the financial sector. His group specialized in analyzing capital markets activity and developing strategic investor relations programs for their clients.
Mr. Davis graduated from Middlebury College in Middlebury, Vermont with a BA in Biology and Psychology.
Endo Pharmaceuticals Holdings Inc. is a specialty pharmaceutical company with market leadership in pain management. Through its wholly owned Endo Pharmaceuticals Inc. subsidiary, the company is engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. More information, including this and past press releases of Endo Pharmaceuticals Holdings Inc., is available at www.endo.com.
Source: Endo Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.